1. Home
  2. BNTX vs BIIB Comparison

BNTX vs BIIB Comparison

Compare BNTX & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNTech SE

BNTX

BioNTech SE

HOLD

Current Price

$110.12

Market Cap

24.8B

Sector

Health Care

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$191.80

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNTX
BIIB
Founded
2008
1978
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.8B
24.2B
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
BNTX
BIIB
Price
$110.12
$191.80
Analyst Decision
Strong Buy
Buy
Analyst Count
11
27
Target Price
$140.31
$194.72
AVG Volume (30 Days)
653.0K
1.3M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
8.79
Revenue
N/A
$9,890,600,000.00
Revenue This Year
$2.58
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$21.85
Revenue Growth
N/A
2.22
52 Week Low
$90.12
$110.04
52 Week High
$124.00
$202.41

Technical Indicators

Market Signals
Indicator
BNTX
BIIB
Relative Strength Index (RSI) 53.72 57.27
Support Level $106.21 $187.20
Resistance Level $112.68 $200.29
Average True Range (ATR) 2.96 6.23
MACD -0.49 0.33
Stochastic Oscillator 60.80 57.74

Price Performance

Historical Comparison
BNTX
BIIB

About BNTX BioNTech SE

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: